Purdue Pharma Lp patents expiration
1. Adhansia Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10500162 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10449159 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10512613 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10292939 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10512612 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10111839 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10292938 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US9974752 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10688060 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10507186 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10568841 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Oct, 2035
(12 years from now) | |
| US10722473 | PURDUE PHARMA LP | Methods and compositions particularly for treatment of attention deficit disorder |
Nov, 2038
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jun 28, 2024 |
Drugs and Companies using METHYLPHENIDATE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2019
Treatment: Method of treating attention deficit hyperactivity disorder (adhd)
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
ADHANSIA XR family patents
2. Hysingla Er patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8529948 | PURDUE PHARMA LP | Pharmaceutical formulation containing gelling agent |
Aug, 2022
(1 year, 1 month ago) | |
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(3 months ago) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(3 months ago) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
| US9486413 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095614 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9545380 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492390 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9095615 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9084816 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9486412 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9775809 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9750703 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9872837 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9572779 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US8808740 | PURDUE PHARMA LP | Encased tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
| US9861584 | PURDUE PHARMA LP | Tamper resistant controlled release dosage forms |
Dec, 2031
(8 years from now) | |
Drugs and Companies using HYDROCODONE BITARTRATE ingredient
Market Authorisation Date: 20 November, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
HYSINGLA ER family patents
3. Oxycontin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(1 year, 6 months from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(1 year, 6 months from now) | |
| US10407434 | PURDUE PHARMA LP | Process for preparing oxycodone compositions |
Mar, 2025
(1 year, 6 months from now) | |
| US10696684 | PURDUE PHARMA LP | Process for preparing oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9675610 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(3 months ago) | |
| US10369109 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Jun, 2023
(3 months ago) | |
| US10130591 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
| US8309060 | PURDUE PHARMA LP | Abuse-proofed dosage form |
Nov, 2023
(a month from now) | |
| US10675278 | PURDUE PHARMA LP | Crush resistant delayed-release dosage forms |
Nov, 2023
(a month from now) | |
| US8808741 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492393 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492391 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492389 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9492392 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9770416 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9775808 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8894988 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US9763933 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304908 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US11304909 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Aug, 2027
(3 years from now) | |
| US8894987 | PURDUE PHARMA LP | Tamper resistant dosage forms |
Mar, 2030
(6 years from now) | |
Drugs and Companies using OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2010
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
OXYCONTIN family patents
4. Targiniq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9073933 | PURDUE PHARMA LP | Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone |
Mar, 2025
(1 year, 6 months from now) | |
| US9522919 | PURDUE PHARMA LP | Oxycodone compositions |
Mar, 2025
(1 year, 6 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9168252 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9345701 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9056051 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9084729 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9511066 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9161937 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9283221 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US8969369 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9283216 | PURDUE PHARMA LP | Abuse-resistant controlled-release opioid dosage form |
May, 2022
(1 year, 4 months ago) | |
| US9555000 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(5 months ago) | |
| US8846090 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(5 months ago) | |
| US8846091 | PURDUE PHARMA LP | Matrix for sustained, invariant and independent release of active compounds |
Apr, 2023
(5 months ago) | |
| US9907793 | PURDUE PHARMA LP | Pharmaceutical preparation containing oxycodone and naloxone |
Apr, 2023
(5 months ago) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 July, 2014
Treatment: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate; Management of pain severe enough to require ...
Dosage: TABLET, EXTENDED RELEASE;ORAL
TARGINIQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic